Navigation Links
OphthaliX Inc. Announces the Completion of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Date:3/15/2013

SOUTH JORDAN, Utah and PETACH TIKVAH, Israel, March 15, 2013 /PRNewswire/ -- OphthaliX Inc. (OTCBB: OPLI) announced today that it has completed patient enrollment for a Phase 3 clinical study of CF101 for the treatment of Dry Eye Syndrome (DES). The randomized, double-masked study is conducted in the United States, Europe and Israel. The study includes 236 patients with moderate-to-severe DES who are randomized to receive two oral doses of CF101 and a placebo for a period of 24 weeks. The results of this study are expected to be announced in the fourth quarter of 2013.

"We are very pleased to have completed the patient enrollment for our Dry Eye Syndrome study," commented Barak Singer , the CEO of OphthaliX. "Receiving additional clinical data is an important step for OphthaliX as we further develop CF101. We are looking forward to the results of this study which will be released during the fourth quarter this year."  

About OphthaliX Inc.
OphthaliX Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

About CF101
CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug which demonstrated efficacy and an excellent safety profile in Phase 2 clinical studies. CF101 is currently developed for ophthalmic indications, including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).

Contact:
KCSA Strategic Communications
'/>"/>

SOURCE OphthaliX Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OphthaliX Reports First Quarter 2012 Financial Results
2. Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
3. ULURU Inc. Announces Closing Of $440,000 Private Placement
4. Cardica Announces Proposed Public Offering of Common Stock
5. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
7. Simbionix Announces License Agreement for Surgical Videos
8. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
9. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
11. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
... University of Michigan Health System has selected a new system-wide ... medical to communications devices, wireless phones and pagers for its ... Hospital. "Moving from a facility where numerous beds ... where beds are now separated into multiple rooms, we anticipated ...
Cached Medicine Technology:Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3New Hospitals to Implement New Communications Technology 2
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... solutions and creators of CMaps Analytics, announced a new location analytics designer for ... professionals to create a wide range of maps experiences in the cloud and ...
(Date:8/27/2015)... ... August 27, 2015 , ... An inventor from Gibertsville, Pa., knows how knees ... against each other while I’m trying to sleep," he said, "so I decided that ... easy-to-use, ergonomic BTKG BED TIME KNEE GUARD helps a user get a better sleep ...
(Date:8/27/2015)... ... 27, 2015 , ... Doctors in the US, the UK and Switzerland say ... especially if given when cells are in the stage known as autophagy. Surviving Mesothelioma ... full article. , Cancer investigators with the University of California, the University of ...
(Date:8/27/2015)... ... August 27, 2015 , ... Generate fully customizable three dimensional ... within Final Cut Pro X. , With ProGeo Refraction, a FCPX Plugin ... do. Users can generate fully customizable three dimensional geometric shape refraction all within Final ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... After conducting ... Smith, Ephraim McDowell Health in Danville, Ky., has hired Burt Piper, as ... leadership experience, Piper will assume his new duties on September 28. , “Burt is ...
Breaking Medicine News(10 mins):Health News:CMaps Analytics Announces New Location Intelligence Integration for SAP Lumira 2Health News:New Research Unveils Potential Method for Improved Response to Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:Announcing a New FCPX Plugin, ProGeo Refraction from Pixel Film Studios. 2Health News:Ephraim McDowell Health Hires New Chief Operating Officer 2Health News:Ephraim McDowell Health Hires New Chief Operating Officer 3
... of actual resveratrol plus 95% OPCs ... and three ... manufacturer,Renaissance Health Publishing, LLC, is disappointed and confused as to ... of Revatrol, and calls on the for-profit laboratory,to remove the ...
... often be the smarter choice, study suggests , MONDAY, Nov. ... symptoms of throat infection, surgery to remove the tonsils is ... watching and waiting to see if symptoms resolve, a Dutch ... University Medical Center Utrecht compared 151 children, ages 2 to ...
... McCandliss, a psychologist at the Sackler Institute for Developmental ... Weill Cornell Medical College, has received a commendation by ... of a Presidential Early Career Award for Scientists and ... by the U.S. government for outstanding scientists and engineers ...
... new article appearing in American Journal of Transplantation describes ... of organ rejection in kidney transplants. The technique, which ... examining DNA sequences, defines how major causes of organ ... behavior. The study is the first to show how ...
... Booker, II, CPA, Presented with Charles Kopke,Medal ... Nov. 19 The American,Diabetes Association (ADA), ... fight against diabetes, announced today that G. ... Arkansas, received the,Association,s prestigious Charles Kopke Medal ...
... an,important step toward protecting patient access to essential ... Fracture Prevention and,Osteoporosis Testing Act of 2007," sponsored ... a reversal of drastic Medicare cuts,to DXA (dual ... the gold standard for measuring bone mass to ...
Cached Medicine News:Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 2Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 3Health News:Tonsillectomy Not Always Cost-Effective for Kids' Throat Woes 2Health News:White House awards Weill Cornell's Bruce McCandliss highest honor for early career scientists 2Health News:Breakthrough in organ rejection diagnosis examines gene behavior 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 3Health News:Congress Moves to Protect Bone Health 2